Real-World Treatment Outcomes and Safety of Afatinib in Advanced Squamous Cell Lung Cancer Progressed after Platinum-Based Doublet Chemotherapy and Immunotherapy (SPACE Study).

Cancers (Basel) · 2023 · PMC10705085 · PMID 38067272

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

All patients harboring ERBB mutations exhibited disease control and showed a trend of higher DCR than those with the ERBB wild type, although it was not statistically significant (100% vs. 60%, p = 0.068).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.